Objective: To analyze the current status and developmental trends of global congenital cataract research
from 2011 to 2020 using the bibliometric method based on the Web of ScienceTM core collection database
and to provide reference information for further research. Methods: This article uses the BiblioShiny
program of scientific bibliometrics based on the R language to analyze the congenital cataract research
literature included in the Web of Science Core Collection (WoSCC) from 2011 to 2020, based on journals,
country and author distribution, keyword co-word analysis, co-citation analysis, collaboration network, etc.
The research knowledge base and research frontier hotspots of global congenital cataract were analyzed.
Results: ①A total of 1 492 studies were included. China and the United States had the largest number of
publications and were in the leading position. ②The publication volume of 《Molecular Vision》 journal
ranked first, with 74 published articles, followed by 《PLoS One》 with 66 published articles. Both are American journals. ③Dr. Scott R. Lambert from the Department of Ophthalmology, Stanford University
School of Medicine, Palo Alto, California had the most publications. ④The knowledge base in the field
of congenital cataracts were congenital cataracts and gene mutations, and the current academic research
hotspot was the topic of gene expression. ⑤The direction of research can be divided into three major
clusters: The first cluster is the incidence of congenital cataract, risk factors, surgical treatment, etc. The
second cluster is mainly molecular genetics, gene mutations, etc. The third cluster is mainly focused on the
structure, stability and function of lens protein. Conclusions: In the field of congenital cataracts from 2011
to 2020, China and the United States are the countries with the largest number of publications. However,
the collaboration network between countries and institutions in the United States is much larger than that
of China. The current mainstream research directions can be divided into clinical treatment and gene and
Lachke SA, Ho JW, Kryukov GV, et al. iSyTE: integratedSystems Tool for Eye gene discovery. Invest Ophthalmol Vis Sci, 2012, 53(3): 1617-1627. DOI: 10.1167/iovs.11-8839.
[7]
Hejtmancik JF. Congenital cataracts and their moleculargenetics. Semin Cell Dev Biol, 2008, 19(2): 134-149. DOI:10.1016/j.semcdb.2007.10.003.
[8]
Foster A, Gilbert C, Rahi J. Epidemiology of cataract inchildhood: a global perspective. J Cataract Refract Surg, 1997,23 Suppl 1: 601-604. DOI: 10.1016/s0886-3350(97)80040-5.
[9]
Graw J. Genetics of crystallins: cataract and beyond. Exp EyeRes, 2009, 88(2): 173-189. DOI: 10.1016/j.exer.2008.10.011.
[10]
Zhao L, Chen XJ, Zhu J, et al. Lanosterol reverses proteinaggregation in cataracts. Nature, 2015, 523(7562): 607-611.DOI: 10.1038/nature14650.
[11]
Lambert SR, Lynn MJ, Hartmann EE, et al. Comparison ofcontact lens and intraocular lens correction of monocular aphakia during infancy: a randomized clinical trial of HOTV optotype acuity at age 4.5 years and clinical findings at age 5 years. JAMA Ophthalmol, 2014, 132(6): 676-682. DOI:10.1001/jamaophthalmol.2014.531.
[12]
Wu XH, Qian KW, Xu GZ, et al. The Role of Retinal Dopaminein C57BL/6 Mouse Refractive Development as Revealed by Intravitreal Administration of 6-Hydroxydopamine. Invest Ophthalmol Vis Sci, 2016, 57(13): 5393-5404. DOI: 10.1167/iovs.16-19543.
[13]
Gillespie RL, O'Sullivan J, Ashworth J, et al. Personalizeddiagnosis and management of congenital cataract by nextgeneration sequencing. Ophthalmology, 2014, 121(11): 2124-2137.e1-2. DOI: 10.1016/j.ophtha.2014.06.006.
[14]
Chen J, Ma Z, Jiao X, et al. Mutations in FYCO1 causeautosomal-recessive congenital cataracts. Am J Hum Genet,2011, 88(6): 827-838. DOI: 10.1016/j.ajhg.2011.05.008.
[15]
Freedman SF, Lynn MJ, Beck AD, et al. Glaucoma-Related Adverse Events in the First 5 Years After Unilateral Cataract Removal in the Infant Aphakia Treatment Study.JAMA Ophthalmol, 2015, 133(8): 907-914. DOI: 10.1001/jamaophthalmol.2015.1329.
Bennett J,Wellman J, Marshall KA, et al. Safety and durabilityof effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial. Lancet, 2016,388(10045): 661-672. DOI: 10.1016/S0140-6736(16)30371-3.
浙公网安备 33030202001892号